ArticleJournal of the National Cancer Institute2008
Speeding up the evaluation of new agents in cancer.
Article in Journal of the National Cancer Institute, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00268476 (STAMPEDE), which is not on this map. Cited by 63 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
STAMPEDE: Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy: A Multi-Stage Multi-Arm Randomised Controlled Trial
Who cites it
63 citing papers in PubMed.
- Trial
- Trial
- Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy.The New England journal of medicine · 2017Trial
- Adding Celecoxib With or Without Zoledronic Acid for Hormone-Naïve Prostate Cancer: Long-Term Survival Results From an Adaptive, Multiarm, Multistage, Platform, Randomized Controlled Trial.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2017Trial
- Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial.Lancet (London, England) · 2016 · on this mapTrial
- Failure-Free Survival and Radiotherapy in Patients With Newly Diagnosed Nonmetastatic Prostate Cancer: Data From Patients in the Control Arm of the STAMPEDE Trial.JAMA oncology · 2016Trial
- Trial
- Celecoxib plus hormone therapy versus hormone therapy alone for hormone-sensitive prostate cancer: first results from the STAMPEDE multiarm, multistage, randomised controlled trial.The Lancet. Oncology · 2012Trial
- Issues in applying multi-arm multi-stage methodology to a clinical trial in prostate cancer: the MRC STAMPEDE trial.Trials · 2009Trial
- Shaping the future of clinical trials through strategic foresight.Clinical trials (London, England) · 2026Article
- Surrogacy validation for time-to-event outcomes with illness-death frailty models.Biometrical journal. Biometrische Zeitschrift · 2024Article
- Translational Challenges and Prospective Solutions in the Implementation of Biomimetic Delivery Systems.Pharmaceutics · 2023Review
- Statistical analysis plan for the motor neuron disease systematic multi-arm adaptive randomised trial (MND-SMART).Trials · 2023Article
- Adaptive experimental design produces superior and more efficient estimates of predator functional response.PloS one · 2023Article
- Combining factorial and multi-arm multi-stage platform designs to evaluate multiple interventions efficiently.Clinical trials (London, England) · 2022Article
- Economic Evaluation of Cost and Time Required for a Platform Trial vs Conventional Trials.JAMA network open · 2022Article
- Experiences of running a stratified medicine adaptive platform trial: Challenges and lessons learned from 10 years of the FOCUS4 trial in metastatic colorectal cancer.Clinical trials (London, England) · 2022Article
- Clinical trials in urological oncology: COVID-19 and the potential need for a new perspective.World journal of urology · 2021Article
- Review
- The Future of Clinical Trial Design in Oncology.Cancer discovery · 2021Review
3 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Despite both the increase in basic biologic knowledge and the fact that many new agents have reached various stages of development during the last 10 years, the number of new treatments that have been approved for patients has not increased as expected. We propose the multi-arm, multi-stage trial design as a way to evaluate treatments faster and more efficiently than current standard trial designs. By using intermediate outcomes and testing a number of new agents (and combinations) simultaneously, the new design requires fewer patients. Three trials using this methodology are presented.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.